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Guillain-Barré syndrome (GBS) has a highly variable clinical course, leading to frequent
transfers within and between hospitals and high associated costs. We defined the current
admissions, transfers and costs in relation to disease severity of GBS.
Methods
Dutch neurologists were requested to report patients diagnosed with GBS between Novem-
ber 2009 and November 2010. Information regarding clinical course and transfers was
obtained via neurologists and general practitioners.
Results
87 GBS patients were included with maximal GBS disability score of 1 or 2 (28%), 3 or
4 (53%), 5 (18%) and 6 (1%). Four mildly affected GBS patients were not hospital admitted.
Of the 83 hospitalized patients 68 (82%) were initially admitted at a neurology department,
4 (5%) at an ICU, 4 (5%) at pediatrics, 4 (5%) at pediatrics neurology and 3 (4%) at internal
medicine. Median hospital stay was 17 days (IQR 11–26 days, absolute range 1–133
days). Transfers between departments or hospitals occurred in 33 (40%) patients and
25 (30%) were transferred 2 times or more. From a cost-effectiveness perspective 21 (25%)
of the admissions was suboptimal. Median costs for hospital admission of GBS patients
were 15,060 Euro (IQR 11,226–23,683). Maximal GBS disability score was significantly cor-
related with total length of stay, number of transfers, ICU admission and costs.
Conclusions
Hospital admissions for GBS patients are highly heterogeneous, with frequent transfers and
higher costs for those with more severe disease. Future research should aim to develop
prediction models to early identify the most cost-effective allocation in individual patients.
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Background
Guillain-Barré syndrome (GBS) is a life-threatening immune-mediated polyradiculoneuropa-
thy [1–2] which requires early diagnosis and hospital admission for accurate monitoring, treat-
ment and supportive care.
GBS was initially treated with plasma exchange (PE) in specialized centers, but since the
introduction of intravenous immunoglobulin (IVIg) in 1992, care for GBS patients was highly
decentralized.[3–5] GBS is a heterogeneous disorder regarding clinical presentation and course
and patients highly differ with respect to the required duration and intensity of hospital care.
[6] Diagnosis may be delayed, especially in patients with atypical clinical presentation, includ-
ing pain[7], and in young children.[8] After admission, patients may rapidly progress and
require intensive monitoring or long-term ventilator support at an Intensive Care Unit (ICU),
which may not be available in smaller hospitals. Diagnostic delay and unexpected deteriora-
tions in 8% to 16% of the patients [4,9], may cause more (acute) transfers between wards and
ICUs or between local and academic hospitals. Previous studies showed that transfers of criti-
cally ill patients and emergency intubations in general result in longer stay at the ICU[10], and
have a negative impact on patient and public health.[10,11]
Currently it is unknown in which departments and hospitals GBS patients are admitted,
how often they are transferred, and what the associated costs are. In this study we aim to evalu-
ate the current practice of hospital admissions, transfers and costs in relation to severity of dis-
ease, with the ultimate aim to provide optimal, cost-effective care for GBS patients.
Methods
Data collection and patient population
Data from the Pandemic Influenza & Vaccination (PIV) study were used, which was originally
designed to investigate the relation between GBS and the pandemic influenza A (H1N1) virus.
[12] Neurologists from all Dutch hospitals were requested to report patients diagnosed with
GBS between November 2009 and November 2010. All the neurologists reported the GBS
patients on a voluntary basis. Consequently, information regarding diagnostic features, clinical
course and transfers was obtained via neurologists, general practitioners and discharge letters
from the hospital that was specifically approved by the Medical Ethical Committee of the Eras-
mus Medical Center in Rotterdam. Written informed consent was not given by participants for
their clinical records to be used in this study. Patient information was anonymized and de-
identified prior to analysis.
Definitions
All patients included fulfilled the diagnostic criteria for GBS from the Brighton Collaboration.
[13] Clinical severity was defined by the GBS disability score at nadir (0 = healthy, 1 = minor
symptoms, 2 = able to walk 10m unassisted but unable to run, 3 = able to walk over 10m open
space with help, 4 = bedridden or chair bound, 5 = requiring ventilation for at least a part of
the day, 6 = dead). For each patient, the number of transfers was determined. Two transfers
equal three beds (e.g. patient admitted at a neurology department, transferred to an ICU and
transferred back to the same neurology department). We counted both transfers between hos-
pitals and between departments within a single hospital. Hospitals were divided in three cate-
gories; local, top clinical and academic centres. Top clinical centres are non-academic “high
cure” centres, which have a high level ICU facility were prolonged mechanical ventilation is
possible.[14]
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Specific Patterns of Admission and Transfer
Five specific transfer patterns were identified which might be suboptimal in terms of cost-
effectiveness:
1. In adults a first admission to another department than neurology or ICU, as this may indi-
cate misdiagnosis.
2. In children 18 year first admission to another department than pediatrics neurology as
children with GBS may be misdiagnosed and require specialized neurological care.[8]
3. Relatively mildly affected patients (maximal GBS disability score 3) admitted to an aca-
demic centre or an ICU, as this might implicate unnecessary high costs.
4. Inter-hospital transfers from local to academic centre in the first two days of hospital admis-
sion, as such a rapid deterioration might have been anticipated on with direct admission to
an academic centre.
5. Mechanical ventilation at the ICU in a local smaller centre, as GBS patients may require
mechanical ventilation for extensive periods of time and require specialized care in larger
centres (at least level 2 ICU in The Netherlands).
Costs of GBS hospital admission
We included costs of admission days in general and academic hospitals, admission days at
ICU, treatment with IVIg and transfers between hospitals. Costs consist of cost prices and vol-
umes. Cost prices are the costs of one single cost unit, e.g. one admissions day. The cost prices
were obtained from standardized cost-data in “Manual for cost research”.[15] Costs for medi-
cal doctors, ward doctors, nurses, other staff members, equipment, medical devices, food, stan-
dard medicines, housing and overhead costs were included in the cost prices per one admission
day at the intensive care unit. The costs for mechanical ventilation are not charged separate
from the costs for one admission day at the intensive care unit, since the costs for the equip-
ment and extra monitoring of the patient are already included in the cost price for an admis-
sion day at the intensive care unit. Volumes are the number of a cost unit, thus the number of
admission days. We did not have specific information on the type of treatment in all individual
patients with GBS. In The Netherlands the first choice treatment according to the national
CBO guideline for GBS is IVIg, which is also available in all centers. According to this guideline
treatment is indicated in patients with GBS disability score 3) or who are transferred to the
ICU and in this study costs for treatment with one course of IVIg was allocated. Consequently,
by multiplying cost prices with volumes the total costs per patient were calculated. Mean and
median costs with interquartile ranges (IQR) in Euros were assessed for the total study popula-
tion and for each maximal GBS disability score subgroup. To assess which patient characteris-
tics mainly determine costs, a linear regression model was fitted with age and maximal GBS
disability score as independent variables and costs as dependent variable. The total costs of all
GBS hospital admissions in The Netherlands per year were determined by multiplying the inci-
dence of GBS per year in the total Dutch population by the median hospital costs.
Statistical analyses
Patient characteristics and hospital admissions were described as medians with IQRs and abso-
lute ranges, or as frequencies. Spearman correlation coefficients (SCC) and corresponding p-
values were calculated for correlations between maximal GBS disability score and total length
of stay, frequency of transfers, ICU admission and days to first transfer. Similarly, correlation
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coefficients were calculated for maximal GBS disability score with days between hospital
admission and transfer to the ICU, length of stay at ICU and total length of stay in patients
admitted to an ICU during hospital stay.
All analyses were performed with SPSS 20.0 (SPSS Inc, Chicago, Illinois), figures were made
with Graphpad Prism 6.01 (Graphpad Software Inc) and R statistical software 2.15.3 (R Foun-
dation for Statistical Computation, Vienna, Austria).
Results
Patient population and characteristics
The study population consisted of 87 GBS patients from a representative combination of 41 dif-
ferent hospitals in The Netherlands (13% academic, 33% top clinical and 58% local centres in our
cohort compared to 9%, 31% and 60% in The Netherlands). The maximal GBS disability scores
were: 1 or 2 (28%), 3 or 4 (53%), 5 (18%) and 6 (1%) (Table 1) and was representative for the gen-
eral population of GBS patients as described in a previous Dutch observational GBS study.[7]
Four (5%) patients had a relatively mild variant of GBS, not reaching a GBS disability score>3.
They were not hospitalized and excluded from further analyses. The hospitalized patients had a
median age of 49 (IQR 30–63), with 11 (13%) children ( 18 years old) and 48 (59%) males.
Hospital admissions
Of 83 hospitalized patients, 12 (15%) were initially referred to an academic centre, 33 (40%) to a
top clinical centre and 38 (46%) to a local centre. The patients were initially referred to various
departments: 68 (82%) to a neurology department, 4 (5%) to an ICU, 3 (4%) to internal medicine,
4 (5%) to pediatrics, and 4 (5%) to pediatric neurology. The median hospital stay was 17 days (IQR
11–26 days; absolute range 1–133 days). A higher maximal GBS disability score was significantly
correlated with a longer total length of stay (SCC 0.59, p< 0.001) (Table 2). Of the 83 admitted
patients, 33 (40%) had at least one transfer to another department or hospital, and more than 50%
of patients were transferred within 2 days after admission. Moreover, 26 (31%) patients were trans-
ferred 2 times or more of which 2 (2%) were transferred 4 times. A higher maximal GBS disability
score was significantly correlated with more transfers (SCC 0.62, p< 0.001). One patient had died
in the hospital. More detailed information regarding the hospital admission is presented in Table 1.
The course of hospital admission for all patients is presented in Fig 1.
ICU admissions
26 (31%) patients stayed at an ICU at some time during follow-up, of which 17 (65%) were venti-
lated. In patients with a GBS disability score of 4 or lower (i.e. not by definition admitted to the
ICU) a higher maximal GBS disability score was significantly correlated to ICU admission (SCC
0.28, p = 0.025) (Table 2). Median time between onset of weakness and admission to the ICU
was 4 days (IQR 2–7 days; absolute range 1–14 days). Median length of stay at the ICU was 12
days (IQR 2–20 days). A higher maximal GBS disability score was significantly correlated to a
longer stay at the ICU (SCC 0.46, p = 0.03). Median duration of ICU admission was 4 days (IQR
1–10 days) for patients with a maximal GBS disability score of 4 and 17 days (IQR 10–24 days)
for patients with a maximal GBS disability score of 5. Main (documented) reasons for transfer to
an ICU were (risk for) mechanical ventilation or short-term admission for observation.
Patients transferred between different types of hospitals
Nine (11%) patients were transferred between different types of centres, including 7 patients
from a local centre to an academic centre (median time of transfer after admission was 2 days;
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Table 1. Characteristics of 83 hospitalized patients with GBS.
Characteristics Missing (%)
Age, median (IQR) 49 (30–64) 0 (0)
Sex, male (%) 49 (56) 1 (1)
Severity at nadir (maximal GBS disability score)* 0 (0)
1 (%) 4 (5)
2 (%) 16 (19)
3 (%) 25 (30)
4 (%) 21 (25)
5 (%) 16 (19)
6 (%) 1 (1)
Preceding diarrhoea (%) 13 (26) 33 (40)
Facial and/or bulbar weakness (%) 30 (36) 4 (5)
Days between onset weakness and admission, median (IQR) 2 (0–5) 6 (8)
Length of stay in hospital 2 (2)
median (IQR) 17 (11–26)
absolute range 1–133
1st hospital 0 (0)
Academic centre (%) 12 (15)
Top clinical centre (%) 33 (40)
Local centre (%) 38 (46)
Departments during hospital stay**
Neurology (%) 74 (89)
ICU (%) 26 (31)
Medium Care/ Neurology- ICU (%) 4 (5)
Internal Medicine (%) 3 (4)
Paediatric Neurology (%) 6 (7)
Paediatrics (%) 4 (5)
Transfers during hospital stay 0 (0)
0 (%) 50 (60)
1 (%) 7 (8)
2 (%) 18 (22)
3 (%) 6 (7)
4 (%) 2 (2)
Days between 1st and 2nd bed, median (IQR)*** 2 (1–4) 5 (15)
ICU admission
mechanical ventilation (%) 17 (65)
Discharge direction Home 41 (49) 2 (2)
Rehabilitation centre 37 (45)
Nursing home 3 (4)
Data are presented as numbers (percentages) or medians (interquartile ranges), excluding patients with
missing data.
* 1 = minor symptoms, 2 = able to walk 10m unassisted but unable to run, 3 = able to walk over 10m open
space with help, 4 = bedridden or chair bound, 5 = needs ventilation for at least a part of the day, 6 = dead.
** These ﬁgures indicate in which departments the GBS patients were admitted at some time point during
hospital stay. A proportion of patients was admitted at various departments, explaining the total number
exceeds 83.
*** Calculated for patients with at least one transfer (n = 33).
doi:10.1371/journal.pone.0143837.t001
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range 1–19 days). Two patients were transferred from a top clinical centre to an academic cen-
tre (after 1 day) or local centre (after 7 days). No patients were transferred from a local to a top
clinical centre, and no patients initially admitted to an academic centre were transferred to
another type of hospital. 78% of the inter-hospital transfers occurred in the first week of admis-
sion and in 56% of the patients within two days. Five (56%) patients were children ( 18 years)
and 3 (33%) patients had a maximal GBS disability score 5.
Specific patterns of admission and transfer
In 21 (25%) patients, the admission and transfers might be classified as suboptimal from a
cost-effectiveness perspective.
1. Three (4%) patients were initially admitted to an internal medicine department.
2. Four (5%) children were initially admitted to a general pediatric department, and trans-
ferred to pediatric neurology department or ICU. Three of them were transferred from a
local to an academic centre.
3. Six (7%) relatively mildly affected patients (maximal GBS disability score 3) were admit-
ted to an academic centre (3; 4%) or ICU (3; 4%).
4. Four (5%) patients were transferred within 2 days of admission from a local to an academic
centre.
5. Seven (8%) patients were mechanically ventilated in a local centre.
Costs of GBS hospital admissions
Seven patients were excluded from cost analyses because of lack of data. Median costs of the
remaining 80 patients were 15,060 Euro (IQR 11,226–23,683 Euro), with an absolute range of
575–208,018 Euro. These costs were composed of admission days in a general hospital (435
Euro per day), academic hospital (575 Euro per day), or ICU (2183 Euro per day), frequency of
inter-hospital transfers (262 Euro per transfer) and treatment with one course of IVIg (8,100
Euro per course). The estimated total costs for all GBS hospital admissions in the Netherlands
per year were 4,832,000 Euro (estimated frequency in total Dutch population of 200 patients
multiplied by the median hospital costs of 24,160 Euro).
Table 2. Spearman correlations with maximal GBS disability score.
Total population (n = 83) Correlation coefﬁcient P-value
Total length of hospital stay 0.59 <0.001
Frequency of transfers 0.62 <0.001
ICU admission* 0.67 <0.001
Days to ﬁrst transfer** 0.15 0.44
ICU admissions (n = 26)*** Correlation coefﬁcient P-value
Days between hospital admission and transfer to ICU 0.20 0.38
Length of stay at ICU 0.46 0.03
Total length of stay 0.37 0.08
* This correlation coefﬁcient is based on the total GBS cohort. The correlation coefﬁcient for patients with a
maximal GBS disability score  4 is 0.28, p = 0.03.
** This correlation coefﬁcient is based on GBS patients with at least one transfer (n = 33).
***All correlation coefﬁcients below are calculated only for patients admitted at an ICU (n = 26).
doi:10.1371/journal.pone.0143837.t002
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Median costs were highly associated with disease severity (expressed as maximal GSB dis-
ability score), ranging from 2,428 Euro (IQR 796–3,806 Euro) for patients with a score of 1, to
59,167 Euro (IQR 45,031–68,369 Euro) for patients with a score of 5 (Table 3). The correlation
between GBS disability score and costs was observed in both children and adults (Fig 2).
The beta for the effect of maximal GBS disability score on costs (adjusted for age) was
16,442 (95% CI 10,939–21,945). This means, for example, that the costs for a patient with a
maximal GBS disability score of 4 are is on average 16,442 Euro higher than those for a patient
with a maximal GBS disability score of 3.
Fig 1. Overview hospital stay of 87 GBS patients. 7 patients not included in figure since limited data were
available on exact days of admission and department(s) of admission. Hatched bars are ICU admissions,
non-hatched bars are admissions in any other department.
doi:10.1371/journal.pone.0143837.g001
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Discussion
In this study the current practice of hospital admissions of patients with GBS was evaluated in
terms of location, duration, transfers and costs, in a representative cohort of GBS patients in
The Netherlands. Transfers within and between hospitals were frequent: 40% of the patients
were transferred at least one time and half of them were transferred within 2 days of admission.
Moreover, in 25% the admission may have been suboptimal form a cost-effectiveness perspec-
tive, including admission to other than (paediatric) neurology departments or ICUs, admission
of mildly affected patients to ICUs and transfers shortly after the initial admission. The related
costs were highly variable between patients and mainly associated with the severity of disease.
These findings may suggest that the care of GBS patients in The Netherlands can be improved
by developing more cost-effective referral strategies based on early diagnosis and prediction of
clinical course and outcome.
Strengths and limitations
Only very few studies have described the practice of current hospital admission of patients
with GBS. Most studies on the clinical course of GBS are based on data from therapeutic trials,
which may be biased to severe cases. Although reporting of GBS cases by the neurologists was
voluntary in this study, we had a representative cohort of GBS patients. In the Netherlands, all
care for all patients with GBS is primarily coordinated by neurologists. Therefor it is highly
unlikely that GBS cases were missed because treatment was coordinated at another depart-
ment. The types of hospital (academic, top clinical and local) were similarly distributed as the
total number of hospitals in the Netherlands. The distribution of age, disease severity at nadir,
proportion of ventilated patients was similar to previous studies on GBS patients in The Neth-
erlands. Previous studies were performed in the United States, which has a different health care
system than European countries, and focused largely on indirect costs.[16] Other studies only
measured the costs of specific treatments for GBS[17–19] or analyzed costs of a specific sub-
group of GBS.[20] In the current study we aimed to determine the current costs of hospital
admissions across the full spectrum of this heterogeneous disorder.
Optimal and cost effective care for GBS
GBS is a complex disorder for cost-effective care because of the various stages in the clinical
course and diversity in clinical course between patients. The complexity is reflected in the high
Table 3. (Minimum) Costs* of hospital admission in GBS patients.**
Maximal GBS disability score N Mean costs in Euros Median costs in Euros (IQR)
1 4 2,428 2,175 (796–3,806)
2 16 5,558 4,258 (3,045–8,644)
3 23 15,866 14,625 (13,320–17,018)
4 20 22,715 19,296 (15,219–26,384)
5 12 75,066 59,167 (45,031–68,369)
6 1 17,529 17,529
Total 76 24,160 15,060 (11,226–23,683)
*These costs include costs for nursing days, treatment and transfers. Costs of diagnostic tests,
physiotherapy and mechanical ventilation were not included in our calculations.
**Excluded were 7 patients from the cost analyses since limited data were available on exact days of
admission and department(s) of admission.
doi:10.1371/journal.pone.0143837.t003
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frequency of transfers between departments and hospitals, especially shortly after initial admis-
sion. Patients initially admitted at the internal medicine department may result in delayed spe-
cialized treatment and monitoring, and an extra transfer. From a costs point of view, ideally
mildly affected patients are admitted to a local or top clinical centre with good general care for
GBS but relatively low costs. More severely affected patients with a higher chance of respiratory
failure and complications may benefit from admission in a top-clinical or academic centre.
Four patients were transferred from a local to an academic centre within two days of admission
and ideally these patients would have been admitted directly to a specialized centre. Adequate
assessment of prognosis could aid decision making at the time of admission. Prognostic models
have been developed to support this assessment, including the externally validated modified
Erasmus GBS Outcome Score (mEGOS) to predict disability outcome in GBS patients at the
time of admission.[21]
Seven patients were initially mechanically ventilated in a local centre, which could have
been prevented when earlier transferred to a top clinical or academic centre. The Erasmus GBS
Respiratory Insufficiency Score (ERGIS) [22] was developed to predict respiratory insufficiency
at time of admission. When a patient has a high chance of respiratory insufficiency, careful
monitoring can potentially avoid an unexpected emergency intubation and acute transfer to
the ICU. The ERGIS could help clinicians to decide to admit or transfer a patient to an aca-
demic centre before the critical stage of disease. Direct admission to a top clinical or academic
Fig 2. Interquartile ranges (grey boxes), 95% confidence intervals (whiskers) andmedian (dark lines
in middle of the boxes) of costs of hospital admission for different maximal GBS disability scores.
Excluded was one patient who died. Circles are (extreme) outliers. Maximal GBS disability score during
hospital admission: 1 = minor symptoms, 2 = able to walk 10m unassisted but unable to run, 3 = able to walk
over 10m open space with help, 4 = bedridden or chair bound, 5 = needs ventilation for at least a part of the
day.
doi:10.1371/journal.pone.0143837.g002
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is preferred above transfer since inter-hospital transfers have negative impact on patient out-
come.[10,11] ERGIS could also help avoiding unnecessary ICU admissions of mild GBS
patients to save costs. In this study, 9 of the ICU admitted patients had no need for mechanical
ventilation. We cannot exclude the possibility that these patients were admitted to an ICU
because of autonomic dysfunction, although this sole indication for admission to an ICU may
be relatively rare.
Children with GBS
Almost half of the children in this cohort were initially admitted to a general pediatrics depart-
ment. Considering the challenging neurologic examination, monitoring and treatment of chil-
dren with GBS, they should preferably be seen by a pediatric neurologist and be admitted to a
centre with a pediatric ICU. All children initially admitted to a pediatric department were later
transferred to a pediatric neurology department or ICU. This referral pattern may indicate a
delay in diagnosis of GBS in young children compared to adults or problems with monitoring
children during the progressive state.[8] In one child, admitted to a pediatric department in a
local centre, the delayed diagnosis and insufficient monitoring resulted in death due to hypoxia
after emergency intubation.[8,23]
Costs of GBS hospital admission
We found that the costs of hospitals admission in GBS are highly variable and mainly depend
on maximal GBS disability score. These are the minimal costs of GBS hospital admissions,
since costs of diagnostic tests, physiotherapy and mechanical ventilation were not included.
Moreover, one course with IVIg for each patient was assigned, although some patients may
have received more (or no) course(s) with IVIg due to treatment related fluctuations or
received other treatment like PE.
Length of stay is the main driver for high costs in GBS hospital admission, especially (long)
admission to an ICU. This also explains the strong correlation between costs and GBS disability
score. Compared to other costs during hospital admission, costs for inter hospital transfers are
relatively low. Also a course with IVIg (8,100 Euro), although considered to be an expensive
treatment, has relatively low costs compared to ICU admission (2,183 Euro per day).
Conclusion
In conclusion, substantial heterogeneity in admission and transfer patters of GBS patients and
associated costs was found. As this study lacks outcome data, no definite conclusions can be
drawn, but we suggested several possibilities for improving to cost-effectiveness of care for
GBS patients. Future research should focus on identifying subgroups of patients who benefit
most from specialized care in an academic centre, e.g. based on prognostic models, and subse-
quently on developing admission guidelines to provide optimal, cost-effective care for GBS
patients.
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